Literature DB >> 15198070

Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman.

Benedict R Capacio1, C E Byers, K A Merk, J R Smith, J H McDonough.   

Abstract

Studies have demonstrated that benzodiazepine compounds are effective at antagonizing seizure activity produced by the organophosphate (OP) cholinesterase inhibitor soman. In this present study we have investigated the pharmacokinetics of midazolam and its associated effects on electroencephalographic (EEG) activity following intramuscular (i.m.) injection to soman-exposed guinea pigs (Crl:(HA)BR). Prior to experiments, the animals were surgically implanted with EEG leads to monitor seizure activity. For the study, animals were administered the following pretreatment/OP/treatment regimen. Pyridostigmine bromide (0.026 mg/kg, i.m.) was given 30 min prior to soman (56 micrograms/kg, 2 x LD50; subcutaneously, s.c.), followed in one minute by atropine sulfate (2 mg/kg, i.m.) and pralidoxime chloride (25 mg/kg, i.m.). All animals receiving this regimen developed seizure activity. Midazolam 0.8 mg/kg, i.m., was administered 5 min after onset of seizure activity. Based on EEG data, animals were categorized as either seizure-terminated or seizure not-terminated at 30 min following anticonvulsant administration. Serial blood samples were collected for the plasma midazolam analysis; the assay was accomplished with a gas chromatograph/mass spectrometer. The mean time to seizure termination was 8.8 +/- 1.6 min. The mean time-plasma concentration data were fit to standard pharmacokinetic models. The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml. These data indicate that i.m. injection of midazolam is effective at terminating ongoing soman-induced seizure activity. Additionally, the relatively short Tmax and latency to seizure termination demonstrate the rapidity of drug absorption and action respectively.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15198070     DOI: 10.1081/dct-120030727

Source DB:  PubMed          Journal:  Drug Chem Toxicol        ISSN: 0148-0545            Impact factor:   3.356


  10 in total

Review 1.  Midazolam as an anticonvulsant antidote for organophosphate intoxication--A pharmacotherapeutic appraisal.

Authors:  Sandesh D Reddy; Doodipala Samba Reddy
Journal:  Epilepsia       Date:  2015-05-29       Impact factor: 5.864

2.  Midazolam-Resistant Seizures and Brain Injury after Acute Intoxication of Diisopropylfluorophosphate, an Organophosphate Pesticide and Surrogate for Nerve Agents.

Authors:  Xin Wu; Ramkumar Kuruba; Doodipala Samba Reddy
Journal:  J Pharmacol Exp Ther       Date:  2018-08-16       Impact factor: 4.030

3.  A rat model of nerve agent exposure applicable to the pediatric population: The anticonvulsant efficacies of atropine and GluK1 antagonists.

Authors:  Steven L Miller; Vassiliki Aroniadou-Anderjaska; Taiza H Figueiredo; Eric M Prager; Camila P Almeida-Suhett; James P Apland; Maria F M Braga
Journal:  Toxicol Appl Pharmacol       Date:  2015-02-15       Impact factor: 4.219

4.  Comparing the Antiseizure and Neuroprotective Efficacy of LY293558, Diazepam, Caramiphen, and LY293558-Caramiphen Combination against Soman in a Rat Model Relevant to the Pediatric Population.

Authors:  James P Apland; Vassiliki Aroniadou-Anderjaska; Taiza H Figueiredo; Volodymyr I Pidoplichko; Katia Rossetti; Maria F M Braga
Journal:  J Pharmacol Exp Ther       Date:  2018-02-21       Impact factor: 4.030

5.  Efficacy of the GluK1/AMPA receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.

Authors:  James P Apland; Vassiliki Aroniadou-Anderjaska; Taiza H Figueiredo; Carol E Green; Robert Swezey; Chun Yang; Felicia Qashu; Maria F M Braga
Journal:  J Pharmacol Exp Ther       Date:  2012-10-05       Impact factor: 4.030

6.  Midazolam-ketamine dual therapy stops cholinergic status epilepticus and reduces Morris water maze deficits.

Authors:  Jerome Niquet; Roger Baldwin; Keith Norman; Lucie Suchomelova; Lucille Lumley; Claude G Wasterlain
Journal:  Epilepsia       Date:  2016-08-08       Impact factor: 5.864

7.  Nerve Agent Toxicity and Treatment.

Authors:  Christopher P Holstege; Stephen G Dobmeier
Journal:  Curr Treat Options Neurol       Date:  2005-03       Impact factor: 3.972

8.  Comparative profile of refractory status epilepticus models following exposure of cholinergic agents pilocarpine, DFP, and soman.

Authors:  Doodipala Samba Reddy; Marcus Zaayman; Ramkumar Kuruba; Xin Wu
Journal:  Neuropharmacology       Date:  2021-04-18       Impact factor: 5.273

9.  Recent advances in the treatment of organophosphorous poisonings.

Authors:  Mahdi Balali-Mood; Hamidreza Saber
Journal:  Iran J Med Sci       Date:  2012-06

10.  Allopregnanolone and perampanel as adjuncts to midazolam for treating diisopropylfluorophosphate-induced status epilepticus in rats.

Authors:  Ashish Dhir; Donald A Bruun; Michelle Guignet; Yi-Hua Tsai; Eduardo González; Jonas Calsbeek; Joan Vu; Naomi Saito; Daniel J Tancredi; Danielle J Harvey; Pamela J Lein; Michael A Rogawski
Journal:  Ann N Y Acad Sci       Date:  2020-09-11       Impact factor: 5.691

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.